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Total n¼90 Autologous n¼51 Allogeneic n¼39
Age, median
(range)
61 (50-73) 61 (50-73) 61 (50-73)
Female 29 (32%) 11 (22%) 18 (46%)
Diagnoses Myeloma 39 (76%)
Lymphoma 9 (18%)
Other 3 (6%)
AML 19 (49%)
MDS 12 (31%)
Other 8 (20%)
Myeloablative conditioning 12 (31%)
Provider
KPS, mean
88  14 87  13 89  15
HCTCI 0
1-2
3
17 (19%)
18 (20%)
55 (61%)
13 (25%)
8 (16%)
30 (59%)
4 (10%)
10 (26%)
25 (64%)
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Introduction: Chronic graft-versus ehost disease (GVHD)
causes a signiﬁcant reduction in patients’ quality of life (QOL)
and functional status. Although older patients undergoing
allogeneic stem cell transplantation may experience higher
morbidity, it is not known if moderate to severe chronic
GVHD has a worse impact on QOL or survival outcomes for
older patients.
Methods: We utilized data of patients with moderate or
severe chronic GVHD (N¼522,1661 follow-up visits, a total of
2,183 visits) from the Chronic GVHD Consortium, a
prospective observational multicenter cohort. We examined
the relationship between age group (adolescent and young
adult “AYA” 18-40, “middle-aged” 41-59, and “older”  60
years) and patient-reported outcomes, functional status,
non-relapse mortality and overall survival in patients with
moderate-severe chronic GVHD. Patient-reported outcomes
included (1) QOL as measured by Functional Assessment of
Cancer Therapy Bone Marrow Transplantation (FACT-BMT)
(2) chronic GVHD symptom burden as measured by the Lee
Symptom Scale; and (3) physical ﬁtness as measured by the
Human Activity Proﬁle (HAP). Functional status was assessed
using the 2-minute walk test (2MWT). Because of multiple
testing, p-values <0.01 were considered signiﬁcant.
Results: This study included 115 (22%) AYA, 279 (53%)
middle-aged and 128 (25%) older patients with moderate
(58%) or severe (42%) chronic GVHD. Older patients (60)
were similar to younger patients in gender, comorbidity
score, time from transplant, prior acute GVHD, severity of
chronic GVHD, but differed in disease distribution and
conditioning regimen intensity. Despite more physical
limitations in older patients as measured by worse func-
tional status [shorter 2MWT (p¼0.002)], and lower HAP
scores (p¼0.001)] than AYA and middle-aged patients,
older patients had better QOL [FACT-BMT (p¼0.01)] scores
compared to middle-aged patients and similar to AYA pa-
tients. Older patients reported less psychological symp-
toms (Lee Psychological Scale (p<0.001), and better
emotional functioning [FACT-Emotional Well-being
(p¼0.001)] than AYA and middle-aged patients. In multi-
variable linear mixed models adjusted for clinical cova-
riates, older patients had better QOL (FACT-BMT) than
middle-aged patients (estimate 5.7, P¼0.004) and compa-
rable to AYA patients (estimate -0.04, p¼0.99). Non-relapse
mortality and overall survival were similar between the
age groups in unadjusted analyses and after adjusting for
clinical covariates.Conclusion: Older patients with moderate or severe chronic
GVHD have preserved QOL and similar overall survival and
non-relapse mortality when compared to younger patients
despite higher physical and functional limitations. Our
ﬁndings suggest that moderate or severe chronic GVHD does
not have a disproportionate effect on QOL or survival in older
patients.
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Background: Selection of older patients who are appropriate
candidates for Hematopoietic Cell Transplant (HCT) has
historically been a largely subjective process. Comprehensive
geriatric assessment (CGA) is used to predict treatment
toxicities in older patients with solid tumors and hemato-
logic malignancies. We applied a well-validated cancer-spe-
ciﬁc CGA in the HCT setting to determine whether pre-HCT
CGA exposes additional vulnerabilities not quantiﬁed by
Karnofsky performance status (KPS) and the HCT Comor-
bidity Index (HCTCI).
Methods: We designed a prospective cohort study enrolling
patients 50 years undergoing HCT (allogeneic or autolo-
gous) at our institution. CGA was performed prior to trans-
plant, and clinical/demographic data were recorded
prospectively.
Results: Ninety patients with a median age of 61 (range
50-73) completed a baseline CGA and underwent HCT. (see
Table) Patient-assessed KPS was signiﬁcantly lower than
provider-assessed KPS (mean 82 15 vs 88 14 respectively,
p¼0.0002), with only moderate correlation (r¼0.53). Thirty-
eight patients (42%) had a deﬁciency in one or more Instru-
mental Activities of Daily Living (IADL). The mean IADL score
was 12.9  2.0 (range 4-14, possible range 0-14). The mean
score on theMedical Outcomes Study Physical Health Scale, a
measure of Activities of Daily Living (ADL), was 66  26
(range 0-100, possible range 0-100). Mental Health
Inventory-5 scores indicating clinical anxiety or depression
were reported by 32 patients (36%), although only 10 (11%)
met criteria for psychiatric disturbance by HCTCI criteria.
There were no signiﬁcant differences between patients
undergoing autologous versus allogeneic HCT in any of the
individual CGA measures. In a subset analysis of 64 patients
Table 1
Patient Characteristics
N
Total eligible for analysis 322
Center
FHCRC 264
VAPSHCC 58
Median Range
Age (years) 50 20-75
Distant Traveled to Transplant
Center (miles)
144.95 0-2719
# Prior Chemo Regimens
2 0-9
%
Marital Status
Married 68.3
Other 31.7
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one or more IADL, and 14 (22%) had ADL scores 50, the
lowest quartile of the group as a whole. Similarly, in
the subset of 35 patients with HCTCI scores 0-2, 13 (37%)
were dependent in one or more IADL and 10 (29%) had ADL
scores 50.
Conclusions: CGA revealed a number of functional impair-
ments in a population of older patients deemed “ﬁt” for HCT.
In subsets of patients with provider-assessed KPS 90 or
HCTCI 0-2, one quarter to one third had quantiﬁable limita-
tions in ADL/IADL. As this study continues to accrue, we will
investigate the association between CGA measures and post-
HCT outcomes, including serial CGA post-HCT, and whether
such associations are independent of traditional prognostic
factors.Histology
Aggressive NHL 61.8
Indolent NHL 13.8
HD 23.6
Unknown <1
Conditioning Regimen
TBI-based 40
Chemotherapy-based 45
Radio-immunotherapy based 15
Chemosensitive disease?
Y 46.6
N 53.4
HCT-CI score
0 30.2
1 or 2 34.5
>3 35.4
LDH elevated?
Y 54
N 44
Unknown 2
Tobacco Use (pack years)
Never 45.3
<15 13
15-29 11
>30 14.6
Unknown 16.1
Alcohol Disorder History
Y 12.4
N 87.6
History of Drug Use
Y 20
N 80
Figure 1. NRM stratiﬁed by the presence of 0, 1 or 2+ of the following:
LDH>ULN, HCT-CI  3, alcohol disorder66
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Little is known about the impact of patient (pt)-speciﬁc
variables in risk-stratiﬁcation prior to autologous HCT for
lymphoma. We investigated the extent to which pt-related
factors other than age, namely comorbidities, alcohol use
disorders, and other demographics impact non-relapse
(NRM) after autologous HCT for lymphoma.
We retrospectively analyzed data from 322 pts treated with
autologous HCT for lymphoma between 2000 and 2005 at
the FHCRC (n¼264) and VAPSHCS (n¼58). Comorbidities
were assessed per the HCT comorbidity index (CI). Alcohol
use disorders included self-identiﬁcation as a current or past
alcoholic, engaging in current or prior “heavy” or “binge”
drinking, convictions for alcohol related crimes, or history of
rehabilitation for alcoholism.
Pre-transplant pt characteristics (Table) were assessed for
associations with NRM in univariate analysis. Factors with a
p-value of <0.1 entered Cox proportional hazard models. In
these models, HCT-CI scores of 3 (HR¼4.52, p¼.004),
elevated LDH (HR¼2.24, p¼.02), and alcohol use disorders
(HR¼2.21, p¼.05) were associated with increases risks for
NRM. Age, histology, center, chemo-sensitivity, smoking, and
drug usewere not. Hence, a simplemodel including none (36%
of pts),1 (48%), or2 (16%) signiﬁcant risk factorswas created.
Overall, NRM incidences were 8% at 1 year and 15% at 5 years.
Pts with 0, 1, or 2 of the signiﬁcant risk factors had NRM
incidences of 2%, 8% and 20% at 1-year and 6%,16% and 28% at
5-years, respectively (Figure 1). Leading causes of death
(COD) among those dying of NRMwithin 1 year (n¼24) were
infection (33%), alveolar damage (25%) and multi-organ
failure (17%). Among those dying beyond 1-year (n¼21),
leading COD were secondary malignancy (43%), infection
(14%) and chronic comorbidities (14%).In summary, pre-transplant LDH and history of alcohol use
disorders adds to the prognostic role of the HCT-CI in risk-
assessment prior to autologous HCT for lymphomas. Age,
